NCT03343678View on ClinicalTrials.gov

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 17, 2018

Primary Completion Date

May 25, 2018

Study Completion Date

November 25, 2020

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

Venetoclax

Venetoclax given alone and then in combination with BI 836826

DRUG

BI 836826

Venetoclax given in combination with BI 836826

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03343678 - This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax | Biotech Hunter | Biotech Hunter